Free Trial
NASDAQ:IFRX

InflaRx (IFRX) Stock Price, News & Analysis

InflaRx logo
$1.60 +0.08 (+4.90%)
As of 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About InflaRx Stock (NASDAQ:IFRX)

Key Stats

Today's Range
$1.46
$1.77
50-Day Range
$0.80
$1.75
52-Week Range
$0.71
$2.82
Volume
760,860 shs
Average Volume
459,696 shs
Market Capitalization
$107.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.20
Consensus Rating
Buy

Company Overview

InflaRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

IFRX MarketRank™: 

InflaRx scored higher than 59% of companies evaluated by MarketBeat, and ranked 422nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    InflaRx has a consensus price target of $6.20, representing about 286.3% upside from its current price of $1.61.

  • Amount of Analyst Coverage

    InflaRx has only been the subject of 1 research reports in the past 90 days.

  • Read more about InflaRx's stock forecast and price target.
  • Earnings Growth

    Earnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InflaRx is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InflaRx is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InflaRx has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about InflaRx's valuation and earnings.
  • Percentage of Shares Shorted

    1.35% of the outstanding shares of InflaRx have been sold short.
  • Short Interest Ratio / Days to Cover

    InflaRx has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InflaRx has recently decreased by 3.77%, indicating that investor sentiment is improving.
  • Dividend Yield

    InflaRx does not currently pay a dividend.

  • Dividend Growth

    InflaRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.35% of the outstanding shares of InflaRx have been sold short.
  • Short Interest Ratio / Days to Cover

    InflaRx has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InflaRx has recently decreased by 3.77%, indicating that investor sentiment is improving.
  • News Sentiment

    InflaRx has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for InflaRx this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added InflaRx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InflaRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InflaRx's insider trading history.
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IFRX Stock News Headlines

Q3 Earnings Estimate for InflaRx Issued By HC Wainwright
HC Wainwright Initiates Coverage on InflaRx (NASDAQ:IFRX)
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
InflaRx Announces Participation in September Investor Conferences
See More Headlines

IFRX Stock Analysis - Frequently Asked Questions

InflaRx's stock was trading at $2.47 at the start of the year. Since then, IFRX shares have decreased by 35.0% and is now trading at $1.6050.

InflaRx N.V. (NASDAQ:IFRX) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.24) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.24). The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.02 million.

InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Top institutional shareholders of InflaRx include 683 Capital Management LLC (3.69%), Raymond James Financial Inc. (0.79%), Adage Capital Partners GP L.L.C. (0.49%) and OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.22%).

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/07/2025
Today
9/10/2025
Next Earnings (Estimated)
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IFRX
CIK
1708688
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$2.00
Potential Upside/Downside
+264.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.85 million
Net Margins
N/A
Pretax Margin
-27,386.74%
Return on Equity
-71.76%
Return on Assets
-57.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.10
Quick Ratio
3.78

Sales & Book Value

Annual Sales
$162.83 thousand
Price / Sales
700.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.13 per share
Price / Book
1.50

Miscellaneous

Outstanding Shares
67,133,000
Free Float
56,190,000
Market Cap
$114.13 million
Optionable
Optionable
Beta
1.43

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IFRX) was last updated on 9/10/2025 by MarketBeat.com Staff
From Our Partners